<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-13003521</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2013-08-24</date_registration>
      <primary_sponsor>411th PLA Hospital, Shanghai.</primary_sponsor>
      <public_title>A Randomized, Double-Blind, Placebo, Controlled, Parallel, Four-Week Study of Compound Food of Algae (AFA) or Placebo in Healthy Human Volunteers to Evaluate the Effect on Circulating Stem Cells.</public_title>
      <acronym />
      <scientific_title>A Randomized, Double-Blind, Placebo, Controlled, Parallel, Four-Week Study of Compound Food of Algae or Placebo in Healthy Human Volunteers to Evaluate the Effect on Circulating Stem Cells.</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2013-10-10</date_enrolment>
      <type_enrolment />
      <target_size>Observation:18;Control:18;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6039</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>Other</phase>
      <hc_freetext>Non-Disease</hc_freetext>
      <i_freetext>Observation:Compond Food of Algae (AFA);Control:Placebo  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Yingqi Zhou</firstname>
        <middlename />
        <lastname />
        <address>15 Dongjiangwan Road, ShangHai, China</address>
        <city />
        <country1 />
        <zip>200081</zip>
        <telephone>+86 021-81867231</telephone>
        <email>zhouyingqi81@163.com</email>
        <affiliation>411th PLA Hospital, Shanghai</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yingqi Zhou</firstname>
        <middlename />
        <lastname />
        <address>15 Dongjiangwan Road, ShangHai, China</address>
        <city />
        <country1 />
        <zip>200081</zip>
        <telephone>+86 021-81867231</telephone>
        <email>zhouyingqi81@163.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Male or Female;
2. Between 18 and 40 years of age, inclusive;
3. No chronic illness (e.g. hematologic disorders, renal disease, hepatitis, Diabetes Mellitus);
4. General health status acceptable for participation in the study;
5. Maximum weight no more than 100 Kg.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>40</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Violation of any inclusion criteria;
2. Failure to perform screening or baseline examinations;
3. Participation in another clinical trial within 30 days before the screening period of this study;
4. Likelihood to be unable to complete the study;
5. History or clinical evidence of drug or ethanol abuse;
6. History or clinical evidence of acute or chronic illness;
7. Significant abnormality of blood chemistry or hematologic parameters; 
8. Use of corticosteroids during the previous 14 days before screening.
Pregnant women and women with childbearing potential who are not using adequate methods to avoid pregnancy, cannot participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>blood cell count;liver function;kidney function;kidney function;stem cell count;T Lymphocyte function;Immunoglubine;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shanghai Standard Biotech Co.,ltd.</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-09-19</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>